FDA accepts Loxo approval application for biomarker-driven cancer drug
If approved, LOXO-101 (larotrectinib) would be the second drug to win a biomarker-based label, after Merck's Keytruda.
Drugmakers increasingly target “baskets” of tumors based on mutations
A new report shows a steady growth in so-called "basket studies" in oncology, along with growing interest by the drug industry.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Loxo Oncology’s shares shoot up on early data slated for ASCO presentation
Loxo's data highlight growing industry interest in so-called "basket" trials and drugs that targeted to genetic markers instead of tumor types.
presented by
Roche’s $1.7B precision medicine acquisition of Ignyta targets cancers with rare mutations
Ignyta's lead molecule, entrectinib, is currently in Phase 2 clinical trials targeting rare mutations in non small cell lung cancer and solid tumors.